- Fever of Unknown Origin (FUO)12:55Polycystic Kidney Disease (PKD), Part 1Free Chapter13:13Paper Chase #1 | Biotin Supplements Screw up Lab Tests? What the…?5:35Living with Cystic Fibrosis: Part II15:45Ectopic Pregnancy20:58Paper Chase #2 | Transdermal Estrogen Keeps the Sex Drive Alive6:58Case of the Month - Hidradenitis Suppurativa19:47Polycystic Kidney Disease (PKD), Part 212:22Paper Chase #3 | The COMPASS Trial5:47Spinal Stenosis13:25Family Medical Leave Act (FMLA)19:03Paper Chase #4 | Are All influenza Tests Created Equal?5:33Grave’s Disease - Part 214:51Deprescribing14:48Paper Chase #5 | Concerning a Cholesterol Drug We’ve Never Heard Of: Anacetrapib5:08The Summary17:36
Autosomal dominant polycystic kidney disease is broken down into two main subtypes: PKD-1 and PKD-2. PKD-1 leads to renal impairment approximately 20 years before PKD-2. While there is a 50% chance that the offspring of a parent with PKD will have the condition, routine screening before the age of 18 is not recommended due to to potential emotional or psychological impact and impact on insurability. Extra renal manifestations include polycystic liver disease and intracranial aneurysms. Hypertension management is key, with ACE or ARB being first line to keep BP below 130/80. Tolvaptan, a vasopressin 2 receptor antagonist, has recently been approved in the European Union, Canada, and Japan for the treatment of PKD, and it may be approved soon in the United States.